跳至主要内容
临床试验/NCT03088137
NCT03088137已完成3 期

Multicentre Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment

IVFarma LLC3 个研究点 分布在 1 个国家目标入组 118 人开始时间: 2017年2月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
IVFarma LLC
入组人数
118
试验地点
3
主要终点
Oocytes (Intention-to-Treat, ITT)

研究概览

简要总结

The purpose of this study is to show equivalence with regard to the number of oocytes retrieved between follitropin alfa (pen-injectors) Primapur® and Gonal-f® in woman undergoing IVF/ICSI

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
20 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Infertility due to tubal factor and/or male factor
  • Age between 20 and 35 years with regular menstrual cycles of 21-35 days
  • First or second cycle in the present series of ART
  • BMI (body mass index) ≥ 18 ≤ 30 kg/m2
  • Basal FSH (follicle stimulating hormone) < 10 IU/L (cycle day 2-5)
  • E2 (estradiol) levels < 50pg/mL (cycle day 2)
  • AMH (anti-mullerian hormone) ≥ 1.0 ng/ml
  • Antral follicle ≥ 4 to ≤ 15 follicles (both ovaries)
  • Presence of both ovaries and normal uterine cavity
  • Informed consent

排除标准

  • Presence of pregnancy
  • Hypersensitivity to follitropin alfa
  • Ovarian cysts
  • History of ≥2 succeeding ART (assisted reproductive technology) cycles IVF (in vitro fertilization) and/or ICSI (Intracytoplasmic sperm injection) before the study cycle
  • Previous history of severe ovarian hyperstimulation syndrome
  • Presence of polycystic ovaries (PCO)
  • Presence of endometriosis and hydrosalpinx
  • Presence of uterine disorders
  • History of poor (< 4 oocytes) or hyper (> 25 oocytes) responses to FSH treatment at dose 150 IU and GnRH-antagonist (gonadotropin-releasing hormone) protocol
  • Premature ovarian failure
  • Ectopic pregnancy (3 month before the study cycle)
  • Presence of clinically significant systemic disease
  • Presence of chronic cardiovascular, hepatic, renal or pulmonary disease
  • Presence of endocrine disorder
  • Neoplasia
  • Male infertility without mobile spermatozoa in the ejaculate, that need MESA (Microsurgical epididymal sperm aspiration)/TESE (testicular sperm extraction)/TESA (testicular sperm aspiration)
  • Smoking > 10 cigarettes/day
  • Narcomania, alcoholism
  • Planned PGS (preimplantation genetic screeneing) /PGD (preimplantation genetic diagnosis)

研究组 & 干预措施

Primapur (Follitropin alfa)

Experimental

干预措施: Follitropin alfa (Primapur) (Drug)

Gonal-f (Follitropin alfa)

Active Comparator

干预措施: Follitropin alfa (Gonal-f) (Drug)

结局指标

主要结局

Oocytes (Intention-to-Treat, ITT)

时间窗: From date of randomization up to 18 days

The total number of retrieved oocytes at the day of ovum pick-up. No more than 37 hours from the introduction of the trigger of ovulation (hCG or GnRH-agonist). The equivalence in the number of retrieved oocytes was tested using a predetermined equivalence margin of +/- 3.4 oocytes.

次要结局

  • Percentage of Patients With the Evidence for Clinical Pregnancy(The 10th week after embryo transfer)
  • Number of Follicles With Size ≥ 16 mm(From date of randomization up to 16 days)
  • Mature Oocytes(From date of randomization up to 18 days)
  • Fertilised Oocytes(From date of randomization up to 19 days)
  • Percentage of Patients With Embryo Transfer(From date of randomization up to 25 days)
  • Total Dose of Follitropin Alfa(From date of randomization up to 16 days)
  • Number of Days of Follitropin Alfa Treatment(From date of randomization up to 16 days)
  • Number of Patients With Follitropin Alfa Dose Correction(From date of randomization up to 16 days)
  • Number of Patients With Cycle Cancellation(From date of randomization up to 16 days)
  • Number of No-responders(From date of randomization up to 8 days)
  • Percentage of Patients With Serum hCG More Than 25 IU/l(From date of randomization up to 42 days)

研究者

发起方
IVFarma LLC
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验